DJIA52573.29 509.19
S&P 5007656.98 65.28
NASDAQ26333.04 251.32
Russell 20002903.94 12.99
German DAX25568.56 207.41
FTSE 10010650.44 41.52
CAC 408179.77 63.01
EuroStoxx 506322.25 52.60
Nikkei 22564011.34 -1259.61
Hang Seng24805.63 -148.84
Shanghai Comp3888.11 -46.29
KOSPI6909.91 -124.01
Bloomberg Comm IDX145.03 -1.94
WTI Crude-fut99.61 -4.34
Brent Crude-fut99.99 -4.03
Natural Gas2.82 -0.02
Gasoline-fut3.32 -0.11
Gold-fut4390.00 30.30
Silver-fut65.02 0.94
Platinum-fut1801.60 18.40
Palladium-fut1315.00 23.50
Copper-fut6.56 0.04
Aluminum-spot3195.00 0.00
Coffee-fut284.25 -5.70
Soybeans-fut1299.00 -32.75
Wheat-fut726.25 -15.25
Bitcoin77161.92 331.49
Ethereum USD2516.93 71.59
Litecoin52.99 0.64
Dogecoin0.08 0.00
EUR/USD1.1624 -0.0007
USD/JPY154.21 0.78
GBP/USD1.3536 0.0001
USD/CHF0.8119 0.0023
USD IDX99.09 0.00
US 10-Yr TR4.971 0.027
GER 10-Yr TR3.5168 0.0143
UK 10-Yr TR5.361 0.0136
JAP 10-Yr TR2.988 0.003
Fed Funds3.75 0
SOFR3.62 -0.02
Connect News Money news for every market and every facet, every day.
Connect Money Events Live and virtual events bringing together the best of information and networking.
Financial Industry Events Live industry events.
Connect Creative A full service marketing and PR agency.
Connect Awards View the A-list of money & submit nominations.
Connect Media Kit Advertise, Promote, Attend, Create – Work with Connect.
About Connect Meet the team behind the machine and taste a little of the secret sauce.
Connect News

Your source for clear, concise news of maximum importance to the financial services industry.

Connect Classroom

Offering on-demand online courses that provide continuing education credits for brokers, attorneys, appraisers and architects. Select from easily accessible video and written courses that cover a variety of CRE topics.

Find Your Course
High-rise commercial buildings

STAY INFORMED

News when you need it. All our Breaking News, right to your inbox.

Sub Markets

Topics

Alternative Assets  + Private Debt  + Private Equity  |  January 24, 2023
Pathalys Pharma Raises $150M Led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics
Joe Palmisano
By: Joe Palmisano

Pathalys Pharma Raises $150M Led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics

Pathalys Pharma, a biotech company developing therapies for chronic kidney disease, has secured $150 million in new Secured Product and equity financing to support phase 3 clinical trials for its leading drug candidate.

Abingworth, a life sciences investment firm owned by global investment firm Carlyle, led the financing. As part of the deal, Pathalys will collaborate with Launch Therapeutics, a clinical development company backed by Carlyle.

Carlyle leapt into the biotech investment scene last year when it bought out Abingworth. At the time of the deal, Abingworth and Carlyle brought Launch Therapeutics into the fold.

The financing marks a significant milestone for Pathalys, which is headed by biopharma veteran Neal Fowler, the former CEO of Morrisville-based Liquidia Corp.

The company launched in March 2022 with backing from Catalys Pacific and DaVita Venture Group.

Connect

Inside The Story

Pathalys PharmaLaunch Therapeutics

About Joe Palmisano

Joe Palmisano is editorial director of Connect Money, where he oversees daily coverage of alternative assets, direct investments, financial advisory and the economy. He brings three decades of experience as a financial journalist, analyst and portfolio manager. Before joining Connect Money, Palmisano wrote for The Wall Street Journal, covering foreign exchange, global fixed-income and equity markets. He later served as a senior research analyst and portfolio manager, producing market analysis and managing foreign exchange and U.S. equity portfolios for FX Concepts. His work has also appeared in SFO Magazine and CMT Association publications. Palmisano earned a bachelor’s degree in finance from The American University and holds the Chartered Market Technician (CMT) designation and is a member of the CFA Institute.
Order Reprints